---
id: 4766
---

# General

## Bibliographic Source(s)

- Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006 Jan 20;55(2):44-6. [9 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16424859)
- Centers for Disease Control and Prevention (CDC). Tiered use of inactivated influenza vaccine in the event of a vaccine shortage. MMWR Morb Mortal Wkly Rep. 2005 Aug 5;54(30):749-50. [4 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16079741)
- Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States and worldwide, May 22-September 3, 2005, and 2005-06 season vaccination recommendations [published erratum in MMWR Morb Mortal Wkly Rep 2005 Sep 23; 54(37):935]. MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):899-902. [10 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16163816)
- Centers for Disease Control and Prevention (CDC). Update: influenza vaccine supply and recommendations for prioritization during the 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2005 Sep 2;54(34):850. [5 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16138422)
- Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005 Jul 29;54(RR-8):1-40. [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086456)

# Identifying Information and Availability

## Bibliographic Source(s)

- Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006 Jan 20;55(2):44-6. [9 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16424859)
- Centers for Disease Control and Prevention (CDC). Tiered use of inactivated influenza vaccine in the event of a vaccine shortage. MMWR Morb Mortal Wkly Rep. 2005 Aug 5;54(30):749-50. [4 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16079741)
- Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States and worldwide, May 22-September 3, 2005, and 2005-06 season vaccination recommendations [published erratum in MMWR Morb Mortal Wkly Rep 2005 Sep 23; 54(37):935]. MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):899-902. [10 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16163816)
- Centers for Disease Control and Prevention (CDC). Update: influenza vaccine supply and recommendations for prioritization during the 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2005 Sep 2;54(34):850. [5 references] [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16138422)
- Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005 Jul 29;54(RR-8):1-40. [ PubMed ](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086456)

# Disclaimer

## NGC Disclaimer

The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the [NGC Inclusion Criteria](/help-and-about/summaries/inclusion-criteria).

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

